FY2024 EPS Estimates for Eyenovia Increased by HC Wainwright

Eyenovia, Inc. (NASDAQ:EYEN) – HC Wainwright upped their FY2024 earnings per share (EPS) estimates for shares of Eyenovia in a report released on Wednesday, November 13th. HC Wainwright analyst M. Caufield now anticipates that the company will post earnings per share of ($0.51) for the year, up from their previous forecast of ($0.67). HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for Eyenovia’s current full-year earnings is ($0.56) per share. HC Wainwright also issued estimates for Eyenovia’s Q4 2024 earnings at ($0.09) EPS, FY2025 earnings at ($0.48) EPS, FY2026 earnings at ($0.31) EPS, FY2027 earnings at $0.14 EPS and FY2028 earnings at $0.56 EPS.

Eyenovia (NASDAQ:EYEN) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.02. Eyenovia had a negative return on equity of 1,108.24% and a negative net margin of 114,639.41%. During the same period in the previous year, the company posted ($0.18) EPS.

Separately, William Blair raised Eyenovia to a “strong-buy” rating in a report on Friday, August 30th.

Eyenovia Stock Down 16.5 %

Shares of EYEN stock opened at $0.34 on Friday. Eyenovia has a twelve month low of $0.33 and a twelve month high of $2.57. The business’s fifty day moving average is $0.50 and its 200 day moving average is $0.71. The company has a quick ratio of 0.27, a current ratio of 0.74 and a debt-to-equity ratio of 0.58.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in EYEN. BNP Paribas Financial Markets lifted its holdings in shares of Eyenovia by 1,444.4% in the 1st quarter. BNP Paribas Financial Markets now owns 219,610 shares of the company’s stock valued at $217,000 after buying an additional 205,390 shares during the period. Vanguard Group Inc. grew its position in Eyenovia by 25.2% in the first quarter. Vanguard Group Inc. now owns 1,790,501 shares of the company’s stock worth $1,765,000 after acquiring an additional 360,924 shares during the period. Nations Financial Group Inc. IA ADV lifted its stake in Eyenovia by 24.4% during the second quarter. Nations Financial Group Inc. IA ADV now owns 50,900 shares of the company’s stock worth $30,000 after purchasing an additional 10,000 shares in the last quarter. Ground Swell Capital LLC acquired a new position in Eyenovia during the second quarter worth $27,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Eyenovia in the second quarter valued at $26,000. 25.84% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Eyenovia

In other news, CEO Michael M. Rowe bought 50,000 shares of the firm’s stock in a transaction on Monday, August 26th. The stock was acquired at an average cost of $0.57 per share, with a total value of $28,500.00. Following the transaction, the chief executive officer now directly owns 82,927 shares in the company, valued at approximately $47,268.39. This trade represents a 151.85 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 7.10% of the stock is currently owned by company insiders.

Eyenovia Company Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.